Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the …
Biotechnology
US, Cambridge [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 4.19 | 9.03 | 8.67 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -32.38 | 0.55 | 0.81 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | -6.54 | 10.85 | 11.61 | |
| Cash | -17.84 | 8.29 | 10.08 | |
| Capex | -56.17 | -0.03 | -0.02 | |
| Free Cash Flow | -23.36 | -1.29 | -1.05 | |
| Revenue | 1329.72 | 0.30 | -0.02 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | -60.06 | 0.91 | 2.29 | |
| Operating Margin | -94.60 | -3.94 | 72.97 | |
| ROA | 16.04 | -0.09 | -0.10 | |
| ROE | 17.61 | -0.10 | -0.13 | |
| ROIC | 36.66 | -0.10 | -0.16 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of NTLA is permitted for members.
5
Growth
The "Growth Entry" for the Focus of NTLA is permitted for members.
6
Leverage & Liquidity